Infectious Diseases News and Research

RSS

Antibiotic resistance: Theme for next Uppsala Health Summit

The theme for the next Uppsala Health Summit, to be held in Uppsala on 2-3 June 2015, is antibiotic resistance -- one of the biggest global health challenges of our day.

2 Dec 2014

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

From Baxter International Inc. 1 Dec 2014

Cepheid gets FDA clearance to market Xpert Norovirus

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).

1 Dec 2014

Leading experts to discuss specific strategies to combat Ebola

Where do we stand in the fight against Ebola -- and what should be done now?

1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

Study provides proof of concept for developing antibodies against human pathogens

Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today's online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens.

28 Nov 2014

Ebola vaccine shows promising results in human trial

An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug.

27 Nov 2014

Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

The U.S. Department of Agriculture (USDA) Rural Development awards Good Samaritan Hospital, a prominent downtown Los Angeles hospital, a $417,560 grant to implement a telemedicine program that will connect members of the medical staff at Good Samaritan Hospital with public health and primary care providers and their patients at six Public Health sites on the island of Guam.

27 Nov 2014

SLU researcher discovers way to block pain pathway

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health and other academic institutions have discovered a way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief.

27 Nov 2014

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.

27 Nov 2014

UTSA's Bernard Arulanandam named fellow of AAAS

Bernard Arulanandam, UTSA Jane and Roland Blumberg Professor in Biology and Assistant Vice President for Research Support, has been named a fellow of the American Association for the Advancement of Science. Arulanandam was elected by his peers for the honor, recognizing his scientific and socially distinguished efforts to advance science and its applications.

26 Nov 2014

New hybrid vehicle to improve delivery of DNA vaccines is under development

Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

26 Nov 2014

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million.

26 Nov 2014

Study finds that starting ART treatment soon after HIV infection improves immune health

HIV-1-infected U.S. military members and beneficiaries treated with antiretroviral therapy (ART) soon after infection were half as likely to develop AIDS and were more likely to reconstitute their immune-fighting CD4+ T-cells to normal levels, researchers reported Nov. 24 in JAMA Internal Medicine.

25 Nov 2014

Gates Foundation provides $2 million grant to help fight major parasitic diseases

Almost $2 million is being invested by the Bill & Melinda Gates Foundation to help fight major parasitic diseases of the developing world.

25 Nov 2014

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

24 Nov 2014

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

24 Nov 2014

Unique ability helps prolific bacterium to afflict humans, animals and even plants

New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism -- a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment.

23 Nov 2014

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology.

21 Nov 2014

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Scientists at the University of Texas Medical Branch were recognized with prestigious awards for their contributions in research at the annual American Society of Tropical Medicine and Hygiene meeting.

21 Nov 2014

Infectious Diseases News and Research

Antibiotic resistance: Theme for next Uppsala Health Summit

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Cepheid gets FDA clearance to market Xpert Norovirus

Leading experts to discuss specific strategies to combat Ebola

iCo Therapeutics announces corporate update and Q3 2014 financial results

Study provides proof of concept for developing antibodies against human pathogens

Ebola vaccine shows promising results in human trial

Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

SLU researcher discovers way to block pain pathway

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

UTSA's Bernard Arulanandam named fellow of AAAS

New hybrid vehicle to improve delivery of DNA vaccines is under development

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

Study finds that starting ART treatment soon after HIV infection improves immune health

Gates Foundation provides $2 million grant to help fight major parasitic diseases

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Unique ability helps prolific bacterium to afflict humans, animals and even plants

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Industry Focus: Infectious Diseases eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News